Abbott holds 2 FDA 510(k) clearances, per the DEPLOY registry.
See all 2 filingsCategoryBiometric wearables
Overview
Abbott laboratories is an American multinational healthcare company headquartered in Abbott Park, Illinois, developing diagnostics, medical devices, nutrition products, and pharmaceuticals. The company's biowearable platform includes the Lingo continuous glucose monitor for health and wellness consumers, based on FreeStyle Libre technology used by over 6 million people with diabetes globally.
Verified record
- Verified deployments
- 1 deployment on file
- Active incidents
- 2 incidents on file
Key facts
Product
Boundary
Business unit
Target population
Data & sources
Press releases
1
Government records
1
Web sources
1
3 sources backing this record.View all →
Models (2)
View all models →Current platform
Abbott FreeStyle Libre
Abbott Laboratories FreeStyle Libre continuous glucose monitoring wearable.
Current platform
Lingo
Lingo is Abbott's over-the-counter continuous glucose monitor biosensor for non-diabetic and wellness consumers, built on the FreeStyle Libre sensor platform, and it is recorded in the biometric form factor as a narrow boundary include and the second glucose example alongside Dexcom Stelo. Made by Abbott, listed on the New York Stock Exchange as ABT through its Abbott Diabetes Care unit, Lingo is a disposable biosensor worn on the back of the upper arm for up to fourteen days using a glucose-oxidase amperometric assay, and it was cleared by the FDA under 510(k) K233655 on May 29, 2024, as a Class II integrated continuous glucose monitoring system for adults eighteen and older who are not on insulin, explicitly not for the diagnosis of any disease including diabetes, a posture directly parallel to Stelo. Its app provides a real-time glucose graph, a Lingo Count daily glucose-spike metric with adaptive targets, food and activity logging, algorithm-driven personalized recommendations, Lingo Challenges behavioral nudges, and Lingo Live sessions with human Abbott nutritionists, with entry pricing of about fifty-four dollars for a two-week single-biosensor starter plan and recurring biweekly and monthly multi-sensor tiers. Glucose is in the biometric definition and Lingo is biometric-primary, and it clears the medical-sensor-without-meaningful-AI exclusion bar on insight-layer substance, since the Lingo Count, adaptive targets, and personalized food-response recommendations are the differentiator versus a bare continuous-glucose graph that Abbott deliberately does not sell to this wellness audience, so the device would exist without the insight layer only in a meaningfully degraded form. A critical cap-flag applies: Lingo is not at parity with Stelo on artificial intelligence. Stelo cleared the bar with a genuine generative-AI layer on Google Cloud Vertex AI and Gemini, whereas Lingo's primary sources describe adaptive and rule-based personalization only, with no documented generative-AI layer and no named AI coaching agent, its coaching being algorithmic plus human nutritionists through Lingo Live, so the registry does not grant Lingo Stelo-equivalent AI standing and records it as the borderline case of the cohort that passes on insight-layer substance rather than on generative-AI grounds. The FDA clearance is the strong anchor, and items not verified include any AI comparable to Stelo's generative AI, a named Lingo coaching agent, the older fifty-three-or-eighty-nine-dollar tier figures since the verified entry is about fifty-four dollars for two weeks and is time-sensitive, and any announced generative-AI roadmap for Lingo.
Partnerships
Every company Abbott has built with, alongside the ones only announced in a press release.
Abbott on the deployment map
View the global map1 verified deployment across 1 region, newest verified May 2024. Explore where Abbott's robots are operating, by place and type.
View the full Abbott deployment record →
Relationships
Current leadership (3)
- Robert B. Ford Chairman & CEOsecondary-verified
- Robert B. Ford Chairman and CEOsecondary-verified
- Robert B. Ford Chairman and CEOsecondary-verified
Founders (2)
- Wallace Calvin Abbottno longer at company
- Wallace Calvin Abbottno longer at company
Former / Previously (3)
- Wallace Calvin Abbott Foundersecondary-verified
- Wallace Calvin Abbott Foundersecondary-verified
- Wallace Calvin Abbott Foundersecondary-verified
Safety record
2 recalls on record (1 critical, 1 moderate). Most recent: May 2024.
Most recent: May 2024
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Incidents affecting Abbott (2)
Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.
Operator customers (1)
- Abbott1 deployment
Recent coverage
Abbott in third-party press
Peer companies
- Google12 models
- Samsung Electronics6 models
- Earendil Robotics4 models
- Bee3 models
- Plaud AI3 models
- Xiaomi3 models
Mentioned on (9)
Registry pages whose text names Abbott.
Robots and products (1)
Partnerships
2 total · 1 operating · 1 just announced
Every company Abbott has built with, alongside the ones only announced in a press release.
Regulatory filings (2)
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Verified media addedVerifiedJun 4, 2026
Say hello to Lingo
- Record createdJun 3, 2026
Added to the verified registry
- Incident recordedMay 24, 2024
Abbott recalls Liberta RC DBS System due to stimulation turning off at 50-day intervals
- Deployment verifiedVerifiedMay 1, 2024
Lingo at Global
- Incident recordedFeb 17, 2022
Abbott voluntary recall of powdered infant formula from Sturgis Michigan facility
Sources (3)
Common questions
What is Abbott?
What does Abbott make?
Is Abbott publicly traded?
Who competes with Abbott?
Who is the CEO of Abbott?
How can I invest in Abbott?
Where is Abbott headquartered?
Who owns Abbott?
Where does Abbott operate robots?
How many robots has Abbott deployed?
Is Abbott a top robotics company?
When was Abbott founded?
Are there any incidents involving Abbott?
Is Abbott safe?
Methodology: Verified · 3 sources (2 primary) · last reviewed 2026-10-22
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-10-22
Sources by quality tier
- 1
- unclassified
- Unclassified source
- 1
- primary-fda-database
- FDA database
- 1
- primary-company-ir
- Company IR disclosure
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Abbott.Peer companies
- Google12 models
- Samsung Electronics6 models
- Earendil Robotics4 models
- Bee3 models
- Plaud AI3 models
- Xiaomi3 models
In the press
Recent coverage mentioning Abbott from third-party publications. Automatically surfaced; not part of the verified registry record.
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
World Intelligent Tissue Autonomous Robots - Market Analysis, Forecast, Size, Trends and Insights
Hugging Face discloses an autonomous agentic breach.
Bowden Cables Market Forecast Points Higher Toward 2035, Driven by Surgical Robotics Adoption
What Globus Medical (GMED)'s Robotics-Focused Institutional Interest Means For Shareholders
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)
China Robotics Firm Signs Star German Goaltender As Brand Ambassador
ISRG's SP Platform: Early-Stage Growth or Next TAM Expansion Driver?
Robotic Catheter Navigation System Market Size | CAGR of 11.0%
Tired of AI and Oil? Buy the Robot.
Abbott Completes $21B Exact Sciences Deal To Expand Cancer Diagnostics
2 Defensive Healthcare Stocks to Buy Right Now
Machine-readable surfaces
- Markdown mirror: /companies/abbott.md
- RSS feed: /companies/abbott/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/9c75b380-8657-4f59-ba05-55e438eea7a9
- Revision history: /companies/abbott/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- Google12 models
- Samsung Electronics6 models
- Earendil Robotics4 models
- Bee3 models
- Plaud AI3 models
- Xiaomi3 models
Video
Gov. Greg Abbott is calling for new restrictions on where AI data centers can be built in Texas, focusing on rural areas and sites near neighborhoods as he argu
ABT stock analysis is absolutely essential right now as Abbott Laboratories executes a massive strategic shift in the diagnostics market. In this video, we brea
Heat Index
Serious50/100
A composite of competitive footprint, funding, press velocity, active partnerships, and supply-chain edges. Different from the Intelligence score below (which is per-form-factor productization). Non-robotics companies cap at 25.
Reality vs attention
Abbott draws attention at the 55th percentile but verifies reality at the 15th percentile among biometric robots. Hype Gap +40.2, 6th widest among biometric robots.
6-month trend
Analysis
Safety profile within acceptable range for category. Deployment footprint remains limited relative to category peers.
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Nov 20, 2026